Reviakine Ilya, Jung Friedrich, Braune Steffen, Brash John L, Latour Robert, Gorbet Maud, van Oeveren Wim
Institute of Functional Interfaces (IFG), Karlsruhe Institute of Technology (KIT), Hermann von Helmholtz Platz 1, 76344 Eggenstein-Leopoldshafen, Germany; Department of Bioengineering, University of Washington, Seattle, WA 98105, USA.
Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT), Helmholtz Zentrum Geesthacht, Kantstrasse 55, 14513 Teltow, Germany.
Blood Rev. 2017 Jan;31(1):11-21. doi: 10.1016/j.blre.2016.07.003. Epub 2016 Jul 25.
There is a widely recognized need to improve the performance of vascular implants and external medical devices that come into contact with blood by reducing adverse reactions they cause, such as thrombosis and inflammation. These reactions lead to major adverse cardiovascular events such as heart attacks and strokes. Currently, they are managed therapeutically. This need remains unmet by the biomaterials research community. Recognized stagnation of the blood-biomaterial interface research translates into waning interest from clinicians, funding agencies, and practitioners of adjacent fields. The purpose of this contribution is to stir things up. It follows the 2014 BloodSurf meeting (74th International IUVSTA Workshop on Blood-Biomaterial Interactions), offers reflections on the situation in the field, and a three-pronged strategy integrating different perspectives on the biological mechanisms underlying blood-biomaterial interactions. The success of this strategy depends on reengaging clinicians and on the renewed cooperation of the funding agencies to support long-term efforts.
人们普遍认识到，需要通过减少血管植入物和与血液接触的外部医疗设备所引起的不良反应（如血栓形成和炎症）来提高其性能。这些反应会导致诸如心脏病发作和中风等重大不良心血管事件。目前，这些问题通过治疗手段来处理。生物材料研究界尚未满足这一需求。血液 - 生物材料界面研究公认的停滞导致临床医生、资助机构以及相邻领域从业者的兴趣逐渐减弱。本文的目的是引发讨论。它基于2014年血液表面会议（第74届国际IUVSTA血液 - 生物材料相互作用研讨会），对该领域的现状进行思考，并提出一个整合了对血液 - 生物材料相互作用潜在生物学机制不同观点的三管齐下的策略。该策略的成功取决于重新吸引临床医生以及资助机构重新开展合作以支持长期努力。
